Infective endocarditis
From IDWiki
Background
- Infection of heart valves, either prosthetic or native
Organisms
- Bacteria
- Staphylococcus aureus (most common)
- Viridans group streptococci
- Coagulase-negative staphylococci
- Other streptococci
- Enterococci
- HACEK group
- Coxiella
- Brucella
- Fungi
Clinical Presentation
- Refer to Modified Duke criteria
- Specific organisms may be associated with specific risk factors
- Injection drug use: Viridans group streptococci and Pseudomonas aeruginosa
- Colon cancer: [Streptococcus bovis]] and Clostridium septicum
Management
- Varies by causative organism and prosthetic vs. native valve
Indication | Antibiotic | Dose | Duration | Notes |
---|---|---|---|---|
MSSA and other oxacillin-susceptible Staphylococcus | ||||
NVE | oxacillin | 12 g/day IV in 4-6 doses | 6 weeks | can treat for 2 weeks in uncomplicated right-sided NVE |
NVE | cefazolin | 6 g/day IV in 3 doses | 6 weeks | in patients with non-anaphylactoid penicillin allergy |
PVE | oxacillin, plus | 12 g/day in 6 doses | ≥6 weeks | use cefazolin or vancomycin if allergy |
rifampin, plus | 900 mg/day IV/PO in 3 doses | |||
gentamicin | 3 mg/kg/day IV/IM in 2-3 doses | 2 weeks | ||
MRSA and other oxacillin-resistant Staphylococcus | ||||
NVE | vancomycin | 30 mg/kg/day IV in 2 doses | 6 weeks | target trough 10-20 μg/mL |
NVE | daptomycin | ≥8 mg/kg/dose | 6 weeks | |
PVE | vancomycin, plus | 30 mg/kg/day in 2 doses | ≥6 weeks | target vancomycin trough of 10-20 μg/mL |
rifampin, plus | 900 mg/day IV/PO in 3 doses | |||
gentamicin | 3 mg/kg/day IV/IM in 2-3 doses | 2 weeks | ||
Enterococcus susceptible to penicillin and gentamicin | ||||
NVE or PVE | ampicillin, plus | 2 g IV q4h | 4-6 weeks | 4 weeks if symptoms <3 months; 6 weeks if symptoms >3 months or if PVE |
gentamicin | 3 mg/kg IBW in 2-3 doses | |||
NVE or PVE | ampicillin, plus | 2 g IV q4h | 6 weeks | alternative regimen if CrCl <50 |
ceftriaxone | 2 g IV q12h | |||
Enterococcus susceptible to penicillin and resistant to aminoglycosides | ||||
NVE or PVE | ampicillin, plus | 2 g IV q4h | 6 weeks | |
ceftriaxone | 2 g IV q12h | |||
Enterococcus resistant to penicillin and susceptible to vancomycin and aminoglycosides | ||||
NVE or PVE | vancomycin, plus | 30 mg/kg/day IV in 2 doses | 6 weeks | |
gentamicin | 3 mg/kg/day IV/IM in 3 doses | |||
Enterococcus resistant to penicillin, aminoglycosides, and vancomycin | ||||
NVE or PVE | linezolid | 600 mg IV/PO q12h | >6 weeks | |
NVE or PVE | daptomycin | 10-12 mg/kg/dose | >6 weeks | |
Viridans Streptococcus or Streptococcus gallolyticus highly susceptible to penicillin (MIC ≤0.12 μg/mL) | ||||
NVE | crystalline penicillin G | 12-18 MU/day IV in 4-6 doses | 4 weeks | |
NVE | ceftriaxone | 2 g IV/IM q24h | 4 weeks | |
NVE | penicillin or ceftriaxone, plus | as above | 2 weeks | |
gentamicin | 3 mg/kg IV/IM q24h | |||
NVE | vancomycin | 30 mg/kg/day IV in 2 doses | 4 weeks | use if allergy, target 10-15 μg/mL |
PVE | crystalline penicillin G, or | 24 MU/day IV in 4-6 doses | 6 weeks | |
ceftriaxone, with or without | 2 g IV/IM q24h | |||
gentamicin | 3 mg/kg IV/IM q24h | 2 weeks | ||
PVE | vancomycin | 30 mg/kg/day IV in 2 doses | 6 weeks | use if allergy |
Viridans Streptococcus or Streptococcus gallolyticus relatively resistant to penicillin (MIC >0.12 μg/mL) | ||||
NVE | crystalline penicillin G, plus | 24 MU/day IV in 4-6 doses | 4 weeks | |
gentamicin | 3 mg/kg IV/IM q24h | |||
NVE | vancomycin | 30 mg/kg/day IV in 2 doses | 4 weeks | use if allergy, target 10-15 μ/mL |
PVE | crystalline penicillin G, or | 24 MU/day IV in 4-6 doses | 6 weeks | |
ceftriaxone, plus | 2 g IV/IM q24h | |||
gentamicin | 3 mg/kg IV/IM q24h | |||
PVE | vancomycin | 30 mg/kg/day IV in 2 doses | 6 weeks | use if allergy |
HACEK bacterium | ||||
NVE | ceftriaxone | 2 g IV/IM q24h | 4 weeks | |
PVE | ceftriaxone | 2 g IV/IM q24h | 6 weeks | |
NVE or PVE | ciprofloxacin | 1000 mg/day PO in 2 doses | 6 weeks |